000212421 001__ 212421
000212421 005__ 20240229162310.0
000212421 0247_ $$2doi$$a10.3390/ijms24021179
000212421 0247_ $$2pmid$$apmid:36674695
000212421 0247_ $$2ISSN$$a1422-0067
000212421 0247_ $$2ISSN$$a1661-6596
000212421 0247_ $$2altmetric$$aaltmetric:140964450
000212421 037__ $$aDKFZ-2023-00140
000212421 041__ $$aEnglish
000212421 082__ $$a540
000212421 1001_ $$aSchöpe, Paul Curtis$$b0
000212421 245__ $$aCantharidin and Its Analogue Norcantharidin Inhibit Metastasis-Inducing Genes S100A4 and MACC1.
000212421 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2023
000212421 3367_ $$2DRIVER$$aarticle
000212421 3367_ $$2DataCite$$aOutput Types/Journal article
000212421 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674469811_15800
000212421 3367_ $$2BibTeX$$aARTICLE
000212421 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000212421 3367_ $$00$$2EndNote$$aJournal Article
000212421 520__ $$aColorectal cancer (CRC) is the third most prevalent and second deadliest cancer worldwide. In addition, metastasis directly causes up to 90% of all CRC deaths, highlighting the metastatic burden of the disease. Biomarkers such as S100A4 and MACC1 aid in identifying patients with a high risk of metastasis formation. High expression of S100A4 or MACC1 and to a greater extent the combination of both biomarkers is a predictor for metastasis and poor patient survival in CRC. MACC1 is a tumor-initiating and metastasis-promoting oncogene, whereas S100A4 has not been shown to initiate tumor formation but can, nevertheless, promote malignant tumor growth and metastasis formation. Cantharidin is a natural drug extracted from various blister beetle species, and its demethylated analogue norcantharidin has been shown in several studies to have an anti-cancer and anti-metastatic effect in different cancer entities such as CRC, breast cancer, and lung cancer. The impact of the natural compound cantharidin and norcantharidin on S100A4 and MACC1 gene expression, cancer cell migration, motility, and colony formation in vitro was tested. Here, for the first time, we have demonstrated that cantharidin and norcantharidin are transcriptional inhibitors of S100A4 and MACC1 mRNA expression, protein expression, and motility in CRC cells. Our results clearly indicate that cantharidin and, to a lesser extent, its analogue norcantharidin are promising compounds for efficient anti-metastatic therapy targeting the metastasis-inducing genes S100A4 and MACC1 for personalized medicine for cancer patients.
000212421 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000212421 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000212421 650_7 $$2Other$$aMACC1
000212421 650_7 $$2Other$$aS100A4
000212421 650_7 $$2Other$$acantharidin
000212421 650_7 $$2Other$$acolorectal cancer
000212421 650_7 $$2Other$$ametastasis
000212421 650_7 $$2Other$$anorcantharidin
000212421 7001_ $$aZinnow, Viktoria$$b1
000212421 7001_ $$aIshfaq, Muhammad Ahtisham$$b2
000212421 7001_ $$aSmith, Janice$$b3
000212421 7001_ $$aHerrmann, Pia$$b4
000212421 7001_ $$aShoemaker, Robert H$$b5
000212421 7001_ $$0P:(DE-HGF)0$$aWalther, Wolfgang$$b6
000212421 7001_ $$00000-0001-7006-282X$$aStein, Ulrike$$b7
000212421 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms24021179$$gVol. 24, no. 2, p. 1179 -$$n2$$p1179$$tInternational journal of molecular sciences$$v24$$x1422-0067$$y2023
000212421 909CO $$ooai:inrepo02.dkfz.de:212421$$pVDB
000212421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000212421 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-7006-282X$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000212421 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000212421 9141_ $$y2023
000212421 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-09-04T08:27:04Z
000212421 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000212421 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000212421 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-25
000212421 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-25
000212421 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2022$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:31:47Z
000212421 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:31:47Z
000212421 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:31:47Z
000212421 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000212421 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2022$$d2023-08-25
000212421 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK BE zentral$$x0
000212421 980__ $$ajournal
000212421 980__ $$aVDB
000212421 980__ $$aI:(DE-He78)BE01-20160331
000212421 980__ $$aUNRESTRICTED